Reliable AIAI-powered data analytics software provider, has quietly announced its launch with €10.1 million in seed funding. The new capital was co-led by Tola Capital and Inovia Capital, with participation from angel investor Mike Volpi.
Reliant AI was founded by Karl Moritz Hermann, Marc Bellemare and Richard Schlegel, leading scientists and researchers in natural language processing and reinforcement learning who have led teams at DeepMind, Google Brain and EY Parthenon. They are passionate about how generative AI can solve information problems to reduce repetitive mental work and accelerate decision-making for businesses. The company is initially targeting the biopharmaceutical sector and will use the new funding to hire talented engineers to expand its technology investments and presence in Europe and North America.
AI Product for Life Sciences
“Information and data are a largely overlooked part of advancing life sciences for a better world. The sheer amount of menial work involved in data-intensive industries today means that many highly skilled professionals are focused on managing data, rather than solving complex problems. We have created an AI system that understands life sciences to radically increase its ability to perform research at scale,” said Karl Moritz Hermann, CEO and co-founder of Reliant AI.
Reliant AI’s first product, Reliant Tabular, is an AI tool that is generating significant interest across major segments of the biopharma industry. The product helps life sciences analysts find scientific evidence to support their decisions through automated systematic reviews, asset analyses, comprehensive analytics, and a customizable data platform. With Reliant AI, everything can be queried.
Reliant Tabular features include proprietary ML models optimized to be experts in biopharmaceutical topics, a holistic approach to fact finding – maximizing recall so nothing is missed, a a user interface that makes it quick and easy to reconcile generated results with baseline evidence and responses in a report-ready format so teams can collaborate on analyses.
The opportunity in the biopharmaceutical sector
“The biopharmaceutical industry has a massive and underserved need for information. Reliant AI combines cutting-edge research and domain expertise to create software that can process a day’s worth of data in 30 seconds. Marc, Karl Moritz, and their technical team bring together decades of AI expertise from the world’s top research groups, such as DeepMind, Google Brain, and Meta, giving Reliant the ability to truly advance the application of generative AI to real-world data problems,” commented Aaron Fleishman, partner at Tola Capital.
“We see a significant market opportunity in the pharmaceutical sector as companies strive to create and partner with new entrants to develop innovative solutions like those offered by Reliant AI,” added Steve Woods, partner at Inovia Capital. “This notable demand in a large and growing market underscores the potential of AI to drive significant advancements in the biopharmaceutical industry.”
